Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €1.11 EUR
Change Today -0.006 / -0.54%
Volume 54.0
TEHN On Other Exchanges
Symbol
Exchange
Frankfurt
As of 1:34 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

peregrine pharmaceuticals (TEHN) Snapshot

Open
€1.10
Previous Close
€1.11
Day High
€1.17
Day Low
€1.10
52 Week High
03/9/15 - €1.51
52 Week Low
10/13/14 - €0.99
Market Cap
221.1M
Average Volume 10 Days
370.0
EPS TTM
--
Shares Outstanding
199.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PEREGRINE PHARMACEUTICALS (TEHN)

peregrine pharmaceuticals (TEHN) Related Businessweek News

No Related Businessweek News Found

peregrine pharmaceuticals (TEHN) Details

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops monoclonal antibodies for the treatment and diagnosis of cancer in the United States and internationally. The company’s lead immunotherapy candidate, bavituximab, which is in Phase III development stage for the treatment of previously-treated non-small cell lung cancer along with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. It is also involved in the development of molecular imaging agent, 124I-PGN650, which is in exploratory clinical trial for the imaging of various solid tumor types. The company provides current good manufacturing practice services from cell line development to commercial biomanufacturing for its third-party customers. It has license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; and Merck KGaA. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.

211 Employees
Last Reported Date: 07/14/15
Founded in 1981

peregrine pharmaceuticals (TEHN) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $557.7K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $423.6K
Vice President, General Counsel and Corporate...
Total Annual Compensation: $393.8K
Vice President of Intellectual Property
Total Annual Compensation: $364.7K
Vice President of Clinical & Regulatory Affai...
Total Annual Compensation: $338.0K
Compensation as of Fiscal Year 2014.

peregrine pharmaceuticals (TEHN) Key Developments

Peregrine Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Twelve Months Ended April 30, 2015; Expects Contract Manufacturing Revenue for Fiscal 2016

Peregrine Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and twelve months ended April 30, 2015. Total revenues for the fourth quarter of 2015 were $9,308,000, compared to $6,474,000 for the same quarter of the prior fiscal year. The company’s consolidated net loss attributable to common stockholders was $13,513,000 or $0.07 per basic and diluted share, for the fourth quarter of 2015, compared to a net loss attributable to common stockholders of $10,649,000, or $0.06 per basic and diluted share, for the same prior year quarter. Loss from operations was $12,169,000 compared to $10,529,000 a year ago. For fiscal 2015, total revenues were $26,781,000, compared to $22,401,000 for the prior fiscal year. The fourth quarter and full year of 2015 increases were attributed to an increase in contract manufacturing revenue. For fiscal 2015, net loss attributable to common stockholders was $54,054,000, or $0.30 per basic and diluted share, compared to $35,763,000, or $0.22 per basic and diluted share, for fiscal 2014. Loss from operations was $50,499,000 compared to $35,706,000 a year ago. The company expects contract manufacturing revenue for fiscal 2016 to be between $30 and $35 million. In addition to providing biomanufacturing services to its third-party customers, Avid will continue to prepare for the potential commercialization of bavituximab.

Peregrine Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt

Peregrine Pharmaceuticals, Inc. filed its 10-K on Jul 14, 2015 for the period ending Apr 30, 2015. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Peregrine Pharmaceuticals, Inc. to Report Q4, 2015 Results on Jul 14, 2015

Peregrine Pharmaceuticals, Inc. announced that they will report Q4, 2015 results at 5:00 PM, Eastern Standard Time on Jul 14, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEHN:GR €1.11 EUR -0.006

TEHN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aduro Biotech Inc $25.37 USD -0.85
Inovio Pharmaceuticals Inc $7.23 USD -0.065
Progenics Pharmaceuticals Inc $8.52 USD -0.14
Transgene SA €2.80 EUR -0.07
Vical Inc $0.63 USD -0.0101
View Industry Companies
 

Industry Analysis

TEHN

Industry Average

Valuation TEHN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.7x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PEREGRINE PHARMACEUTICALS, please visit www.peregrineinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.